Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

INTRODUCTION: BAY 94-9027 is a newly developed extended half-life product to treat haemophilia, allowing for fewer injections than with standard products. This post hoc analysis aimed to compare physicians’ and patients’ opinions on BAY 94-9027 prophylaxis, and explore how qualitative interview data...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, Simpson, Mindy L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467448/
https://ncbi.nlm.nih.gov/pubmed/32410165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01374-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia